Skip to content

Not medical advice. Talk to your provider before using any peptide. Full disclaimer

Liraglutide peptide icon, one bubble per amino acidLiraglutide31 residuesHAEGTFTSDVSSYLEGQAAKEFIAWLVRGRGEach bubble = one amino acid. Size = residue mass. Color = chemical class.

Liraglutide

Beginner tier: 600 mcg, daily · FDA label

Weight LossFDA Approved
13 h half-life·Injection

Also known as: Victoza, Saxenda, NN2211

Over 9,300 patients in the LEADER trial. A 13% drop in major cardiovascular events. Liraglutide (Victoza, Saxenda) is a GLP-1 receptor agonist with two FDA approvals and more than 15 years of real-world safety data. The SCALE trial landed on 8% mean weight loss at 56 weeks with the 3 mg dose. That's less than semaglutide, and honesty about that matters. Liraglutide's 13-hour half-life means side effects wash out in about a day if you stop. That short clearance time is why many clinicians still reach for it first, especially for patients new to GLP-1 therapy or those with a history of GI sensitivity.

What Is Liraglutide?

A 13% reduction in heart attacks, strokes, and cardiovascular death across 9,340 patients over 3.8 years. That LEADER trial finding [1] made liraglutide the first GLP-1 drug proven to protect the heart. Liraglutide (also sold as Victoza for diabetes and Saxenda for weight management) is a modified version of human GLP-1 with 97% amino acid homology to the native hormone. A palmitic acid chain at position 26 lets it bind albumin in the blood. That binding shields it from DPP-IV breakdown and extends the half-life from about 2 minutes to roughly 13 hours, long enough for once-daily dosing.

On the weight side, the SCALE Obesity and Prediabetes trial (n=3,731)[2] showed 8.0% mean body weight loss at 56 weeks on the 3 mg dose versus 2.6% on placebo. A head-to-head comparison in STEP 8 (PMC8753508) put those numbers in context: semaglutide 2.4 mg weekly produced 15.8% loss versus 6.4% for liraglutide 3 mg daily over 68 weeks.

The practical picture for most users looks like this: a pre-filled pen (no mixing needed), weekly dose increases from 0.6 mg up to 3.0 mg, and GI side effects that peak during titration but usually settle within a few weeks. Appetite suppression kicks in within days of the first injection. FDA approved Teva's generic of Saxenda in August 2025.

How Liraglutide Works

A C-16 fatty acid (palmitic acid) attached via a glutamic acid spacer at position 26. That single modification gives liraglutide its clinical utility. The palmitic acid promotes non-covalent binding to serum albumin, which does two things: it shields the molecule from DPP-IV and neutral endopeptidase degradation, and it slows absorption from the subcutaneous injection site. Native GLP-1 has a plasma half-life of about 2 minutes. Liraglutide's is roughly 13 hours.

Once circulating, liraglutide activates GLP-1 receptors across multiple tissues. In the pancreas, it boosts glucose-dependent insulin secretion and suppresses inappropriate glucagon release. The glucose-dependent part is important; hypoglycemia risk stays low when liraglutide is used alone because insulin release only ramps up when blood sugar is raised.

In the GI tract, gastric emptying slows by 10 to 15%. In the brain, liraglutide acts on hypothalamic and brainstem GLP-1 receptors to reduce appetite and food reward signaling. The cardiovascular protection spotted in LEADER [1] likely involves direct effects on vascular endothelial function and anti-inflammatory pathways, though the exact mechanisms are still being mapped out.

Liraglutide Benefits

  • Liraglutide benefits center on proven weight loss, cardiovascular protection, and a safety profile backed by more than a decade of post-market data.
  • 8.0% mean body weight loss at 56 weeks on 3 mg daily in the SCALE trial (n=3,731)[2]. Real-world results typically land between 5% and 8%.
  • Cardiovascular protection confirmed in LEADER (n=9,340): 13% reduction in major adverse cardiovascular events over 3.8 years of follow-up [1]. That trial was one of the first to prove a diabetes drug could protect the heart.
  • Short half-life (13 hours) means side effects clear within about a day if you need to pause. Semaglutide's weekly dosing locks you in for seven days if problems arise.
  • No reconstitution or mixing. Saxenda ships as a pre-filled pen. Dial your dose and inject.
  • Approved for adolescent obesity (ages 12 and up) since 2020, making it one of the few GLP-1 options with a pediatric indication.
  • HbA1c reductions of 1.1% to 1.4% at the Victoza dose range (1.2 to 1.8 mg daily), with blood sugar improvements reported even in non-diabetic users.

Liraglutide: Science vs Community Consensus

Aligned
Scientific Evidence
Strong
Based on 10 key studies·FDA-approved

FDA-approved for chronic weight management (Saxenda, 3 mg/day) and type 2 diabetes (Victoza, up to 1.8 mg/day).

Dosing studied: 0.6 mg/day (titration start) → 3.0 mg/day (Saxenda maintenance); 1.2–1.8 mg/day (Victoza/T2D)
Read the evidence (key study, limitations)

Strong RCT evidence for ~8% weight loss at 56 weeks and 13% MACE reduction in high-CV-risk T2D. Well-characterized safety profile after 15+ years on market. Less effective than semaglutide or tirzepatide for weight loss.

Key Study

SCALE Obesity and Prediabetes (PMID 26132939): n=3,731, 3 mg/day vs placebo, 56 wk: 8.0% vs 2.6% mean weight loss. LEADER (PMID 27295427): n=9,340 T2D high-CV-risk, 3.8-yr median follow-up: 13% MACE reduction (HR 0.87, 95% CI 0.78-0.97). STEP 8 head-to-head (PMC8753508): semaglutide 2.4 mg/wk vs liraglutide 3 mg/day, 68 wk: −15.8% vs −6.4% weight loss.

Limitations

Substantially less effective than semaglutide (-6.4% vs -15.8% in STEP 8) and tirzepatide. Daily injection vs once-weekly alternatives. Weight regain expected on discontinuation. Black box warning for medullary thyroid carcinoma (rodent data only; LEADER found 0 MTC in liraglutide arm vs 1 placebo). Slight numerical imbalance in total malignancies in LEADER (10.1% liraglutide vs 9.0% placebo, HR ~1.06, not statistically significant: clinical relevance unclear). Pancreatitis rate similar to placebo in LEADER.

Community Experience
Strong
3.6/5
Based on 5,585+ PubMed citations

Regarded as the "old reliable" GLP-1: effective, well-understood, and now accessible via generic and compounding.

Community dosing: 0.6 mg/day titration start; most users target 1.2–1.8 mg/day as effective maintenance; some push to 3.0 mg for max effect
Read the reports (what users report 6, common issues 7)

Most users follow the FDA titration closely. The daily injection and lower weight loss vs semaglutide drive switching; many transition to semaglutide or tirzepatide after experiencing or researching the options.

What users report (6)
  • Appetite suppression begins within days of first dose
  • Nausea clears faster than with semaglutide: drug washes out in ~1 day if you need to pause
  • Daily short half-life allows dose flexibility and faster side-effect recovery
  • Now cheaper via the Teva generic and compounded 503A versions
  • Consistent 1–2 lb/week loss once at therapeutic dose
  • Improves fasting glucose and insulin sensitivity: reported even in non-diabetics
Common issues (7)
  • Nausea is prevalent during titration: ~40% at 3 mg dose
  • Daily injection burden vs once-weekly alternatives
  • Many switch to semaglutide for better weight loss after stalling
  • Hair thinning reported (telogen effluvium from rapid weight loss, not direct drug effect)
  • Constipation common at maintenance dose
  • GI side effects can limit ability to reach the 3 mg dose
  • Cost: brand-name Saxenda is expensive without insurance
Science & Community Aligned

Community closely follows FDA titration protocol. Real-world outcomes (~5–8% weight loss at maintenance) are consistent with trial data. The primary divergence is that many community users elect to stay at sub-maximal doses (1.2–1.8 mg) rather than pushing to 3.0 mg: driven by tolerability, not ignorance of dosing. No significant off-label dose escalation patterns observed.

Liraglutide Dosage Guide

FDA LabelSaxenda FDA Prescribing Information (2026), NDA 206321 (n=3,731 (SCALE Obesity and Prediabetes))Source (opens in a new tab)
LevelDose / InjectionFrequency
Beginner600 mcgDaily
Moderate1.8 mgDaily
Aggressive3 mgDaily
Note:

Liraglutide comes as a pre-filled pen, so there's no reconstitution math to worry about. Saxenda pens hold 18 mg total and deliver doses from 0.6 mg to 3.0 mg via a dial selector. At the 3 mg maintenance dose, one pen lasts 6 days.

For compounded liraglutide from 503A pharmacies, the common concentration is 6 mg/mL. With that concentration in a standard insulin syringe: 10 units equals 0.6 mg, 20 units equals 1.2 mg, 30 units equals 1.8 mg, 40 units equals 2.4 mg, and 50 units equals 3.0 mg.

The thing most beginners miss: if you skip more than 3 consecutive days, you need to restart at 0.6 mg and re-titrate. Jumping back to your prior dose after a gap causes disproportionate GI distress. Keep your pens on schedule or plan for the ramp back up. Store unused pens in the fridge (2 to 8 degrees Celsius). Once you start using a pen, it can stay at room temperature (up to 30 degrees Celsius) for 30 days.

Cycling

No scheduled off period.

Designed for continuous long-term use. Weight regain expected after discontinuation. If you miss more than 3 consecutive days, restart at 0.6mg and re-titrate.

Calculate your Liraglutide dose
Dosing tiers, timing, and cycle length

Or use the universal Peptide Calculator for any peptide.

Liraglutide Protocols by Goal

beginnerFDA LabelOngoing: designed for long-term continuous use
Titration Week 1
Wk 1
0.6 mg · Daily · Subcutaneous
Titration Week 2
Wk 1
1.2 mg · Daily · Subcutaneous
Titration Week 3
Wk 1
1.8 mg · Daily · Subcutaneous
Titration Week 4
Wk 1
2.4 mg · Daily · Subcutaneous
Maintenance
Wk 5–52+
3.0 mg · Daily · Subcutaneous

Expected: ~8% mean body weight loss at 56 weeks (SCALE trial); real-world 5–8% typical

Monitor: Check fasting glucose, HbA1c, lipid panel, and gallbladder symptoms at baseline and 3–6 months. Monitor body weight at each visit. Screen for pancreatitis symptoms (severe abdominal pain radiating to back: stop immediately).

How to Inject Liraglutide

  1. 1
    Step 1

    Remove the pen from the refrigerator 15 to 30 minutes before injecting. Room-temperature solution reduces injection discomfort.

  2. 2
    Inspect the solution

    It should be clear and colorless. Do not use if cloudy or if you see particles.

  3. 3
    Attach a new pen needle (32-gauge is standard for Saxenda)

    Remove both the outer and inner needle caps.

  4. 4
    Step 4

    If using the pen for the first time or if it's been stored without a needle, prime by dialing to 0.6 mg and pressing the dose button until solution appears at the needle tip.

  5. 5
    Dial your prescribed dose

    Titration schedule for Saxenda: 0.6 mg daily for week 1, 1.2 mg for week 2, 1.8 mg for week 3, 2.4 mg for week 4, then 3.0 mg ongoing.

  6. 6
    Step 6

    Choose your injection site: abdomen or upper arm for best absorption. The thigh works but absorption drops by about 22%. Rotate sites; avoid the same spot for at least a week.

  7. 7
    Step 7

    Pinch the skin, insert the needle at 90 degrees, press the dose button, and hold for 6 seconds before withdrawing.

  8. 8
    Remove and safely dispose of the needle after each use

    Replace the pen cap. Never store the pen with a needle attached.

For compounded liraglutide (6 mg/mL concentration): draw 10 units on a standard insulin syringe for 0.6 mg, 20 units for 1.2 mg, 30 units for 1.8 mg, 40 units for 2.4 mg, or 50 units for 3.0 mg. Inject subcutaneously at the same sites. 29 to 31 gauge, half-inch needle.

Timing is flexible. Inject at the same time each day, with or without meals.

Liraglutide Stacking Protocols

Works With

Avoid

Insulin (any type)

Using liraglutide with insulin may raise the risk of hypoglycemia, including severe hypoglycemia. The Victoza label says to consider a lower insulin dose when starting liraglutide (section 7.2). Saxenda says a lower insulin dose may reduce the risk and adds blood glucose checks in type 2 diabetes (section 5.4).

Sulfonylureas (glipizide, glyburide, etc.)

Using liraglutide with a sulfonylurea may raise the risk of hypoglycemia, including severe hypoglycemia. The Victoza label says to consider a lower sulfonylurea dose when starting liraglutide (section 7.2). Saxenda says a lower dose may reduce the risk (section 5.4).

Digoxin

Liraglutide reduces digoxin AUC by ~16% and Cmax by ~31% via delayed gastric emptying. Monitor digoxin levels if co-administering.

Estimated Cost

Brand Price
Brand Saxenda: ~$1,300–$1,800/month retail (5 pre-filled pens). Discounted cash price: as low as ~$372/month. Novo Nordisk savings card: eligible commercially-insured patients may pay $25/month. Victoza (diabetes): similar pricing range.
Generic / Research
Teva generic liraglutide injection: ~$1,165/month (WAC, launched August 2025, FDA-approved, bioequivalent). Drugs@FDA lists 11 approved liraglutide generics as of October 14, 2026 (8 for Victoza, 3 for Saxenda).
Compounded
Compounded liraglutide (503A pharmacies): ~$150–$249/month. Liraglutide remains on FDA's drug shortage list as of October 2026. PCAB-accredited 503A pharmacies and telehealth providers offer prescription access. Quality varies by pharmacy; a COA documents each batch.

Pricing updated 2026-04-09

Liraglutide Side Effects

Liraglutide carries a black box warning for medullary thyroid carcinoma. In rodent studies, liraglutide caused dose-dependent thyroid C-cell tumors at exposures 8 times the human dose. No confirmed human cases appeared in the LEADER trial (0 MTC in the liraglutide arm versus 1 in placebo, n=9,340). Still, the warning makes liraglutide off-limits for anyone with a personal or family history of MTC or Multiple Endocrine Neoplasia syndrome type 2 (MEN2).

GI side effects are the most common reason people quit. Nausea hits roughly 40% of users at the 3 mg dose. Vomiting, diarrhea, and constipation affect 15 to 20%. The pattern is predictable: symptoms peak during each dose increase and fade over 2 to 3 weeks at a stable dose. Slow titration (advancing by 0.6 mg per week as labeled) reduces the severity. Some community users extend to 2 weeks per step if nausea is severe.

Pancreatitis occurs in under 0.4% of patients. The LEADER trial found rates similar to placebo, but the risk is real. Severe abdominal pain radiating to the back, with or without vomiting, means stop the drug and get evaluated immediately.

Gallbladder disease showed up in about 2.2% of SCALE trial participants. GLP-1 receptor agonists slow gallbladder emptying, and rapid weight loss adds to gallstone risk. Right upper quadrant pain warrants an ultrasound.

LEADER turned up a slight numerical imbalance in total malignancies (10.1% liraglutide versus 9.0% placebo, HR approximately 1.06). This was not statistically significant. The clinical meaning is unclear, but it was observed and should be noted.

Hypoglycemia is rare when liraglutide is used alone. It becomes a genuine risk when combined with insulin or sulfonylureas; dose reductions of those medications are often needed. Injection site reactions are mild and infrequent.

Hair thinning (telogen effluvium) shows up in community reports. This is driven by rapid weight loss rather than a direct drug effect. It's typically self-limiting.

When to seek medical attention: severe abdominal pain, persistent vomiting, signs of allergic reaction, or any visual changes. Stop liraglutide at least 2 months before planned conception; the drug was detected in milk of lactating rats, and human data on infant risk are insufficient.

Common Issues & Solutions

Nausea peaks at each dose increase: if severe, hold current dose for 2 extra weeks before advancing rather than stopping. Ginger tea, small bland meals, and morning dosing (after breakfast) help most users.

If you miss more than 3 consecutive days, restart titration at 0.6 mg: jumping back to your prior dose after a gap causes disproportionate GI side effects.

Constipation at maintenance dose (3 mg) is common: increase fluid intake to ≥2.5L/day, add 25–35 g dietary fiber, consider osmotic laxative (MiraLax) if persistent.

Injection site lumps or reactions: rotate sites each injection: abdomen, thigh, upper arm. Avoid the same spot for at least 1 week. Brand Saxenda pen is a large 32-gauge needle; room-temperature pen reduces injection discomfort.

Weight plateau after initial loss: confirm you are at the 3.0 mg dose. If already at 3 mg and plateaued, review caloric intake: liraglutide suppresses appetite but does not override a significant caloric surplus. Consider switching to semaglutide or tirzepatide for additional efficacy.

Ask AI about this page

Ask AI for a second opinion on Liraglutide dosing and side effects

Contraindications

  • Personal or family history of medullary thyroid carcinoma (MTC)
  • Multiple Endocrine Neoplasia syndrome type 2 (MEN2)
  • History of pancreatitis
  • Pregnancy or planning to become pregnant (stop at least 2 months before conception)
  • Breastfeeding: liraglutide was detected in milk of lactating rats; human data are insufficient to assess infant risk
  • Known hypersensitivity to liraglutide
  • Severe renal impairment (eGFR <15 mL/min): limited data, use with caution per FDA label Section 8.6

Drug Interactions

  • Insulin and sulfonylureas: increased hypoglycemia risk, dose reduction often needed
  • Oral medications may have delayed absorption due to slowed gastric emptying
  • Digoxin: AUC reduced by approximately 16%; monitor levels
  • Oral contraceptives: Cmax fell 12% for ethinyl estradiol and 13% for levonorgestrel, and Tmax came 1.5 hours later. AUC did not drop (Saxenda and Victoza labels, section 12.3)
  • Oral contraceptives and oral hormonal therapies: the Saxenda and Victoza labels call for no backup contraception and set no dose timing. Both advise caution with oral drugs, since liraglutide slows gastric emptying (section 7.1)

Product Quality

Recommended Monitoring

TestWhenTarget
Body weightBaseline, then monthlyNot listed
Fasting glucose and HbA1cBaseline, then every 3 monthsHbA1c <7.0% (T2D), fasting glucose 70–100 mg/dL
Lipid panelBaseline, then every 6 monthsNot listed
Liver function tests (AST, ALT)Baseline, then every 6 monthsNot listed
Amylase / LipaseIf symptoms of pancreatitis develop (severe abdominal pain radiating to back, nausea/vomiting)Not listed
Gallbladder ultrasoundIf right upper quadrant pain or cholecystitis symptoms developNot listed
Heart rateEach clinical visitNot listed
Serum calcitoninBaseline and annually if monitoring thyroid cancer risk (family history of MTC or MEN2: though liraglutide is contraindicated in these patients)Not listed
Body weight

Primary efficacy measure; if <4% weight loss at 16 weeks on 3 mg, reassess therapy

Fasting glucose and HbA1c

For T2D patients or those with prediabetes. Liraglutide improves glycemic control even in non-diabetics

Lipid panel

Weight loss and GLP-1 action improve triglycerides and LDL; monitor for gallbladder-related lipid changes

Liver function tests (AST, ALT)

Not required by FDA label but prudent for long-term users given metabolic changes and fatty liver context

Amylase / Lipase

Pancreatitis risk exists with GLP-1 class; rate similar to placebo in LEADER but monitor for symptoms

Gallbladder ultrasound

Gallbladder disease incidence 2.2% in SCALE trial; GLP-1s slow gallbladder emptying

Heart rate

GLP-1 RAs modestly increase resting heart rate; relevant for patients with pre-existing arrhythmia or cardiac history

Serum calcitonin

Black box warning for medullary thyroid carcinoma based on rodent data; no confirmed human cases in LEADER

Liraglutide Before and After

Weeks 1-4

Titration phase: dose increases weekly from 0.6mg to 2.4mg. Appetite suppression begins within days. Nausea most common but typically improves.

Weeks 5-8

Full dose (3mg) reached. Noticeable reduction in hunger. Most see 2-4% body weight loss by week 8.

Weeks 9-26

Steady weight loss of 0.5-1 lb per week. Blood sugar improvements measurable on labs.

Weeks 27-56

Weight loss approaches 8% average from SCALE trial. Cardiovascular markers improve. Rate slows near equilibrium.

What to Expect

Weeks 1 through 4, Titration. The dose advances weekly from 0.6 mg to 2.4 mg. Appetite suppression is measurable by week 2 in most users. GI side effects peak during each dose step; nausea is the most common complaint and hits roughly 40% at therapeutic doses. Community reports consistently describe noticeably reduced appetite within 3 to 5 days of the first injection. Most people see 1 to 3 pounds of loss in the first month, driven by reduced caloric intake rather than any direct metabolic effect.

Weeks 5 through 8, Full Dose. At 3.0 mg daily, GLP-1 receptor engagement reaches its maximum. SCALE trial data predicts 2 to 4% body weight loss by week 8. Users describe the reduction in "food noise" as the most noticeable change. Smaller portions feel satisfying. GI side effects typically start improving from their peak. Community reports land on 2 to 5 pounds of additional loss in this window. Constipation and fatigue are common but usually resolve. Mild nausea continues to diminish.

Weeks 9 through 26, Active Loss Phase. Steady progressive weight loss averages 0.5 to 1 pound per week. Blood glucose improvements become measurable on lab work. SCALE data shows approximately 6% weight loss by week 26. Some users hit plateaus at the 1 to 2 month mark; these typically resolve with caloric adjustment or dose confirmation. Hair thinning (telogen effluvium from the weight loss itself, not a direct drug effect) may appear during this window. It is typically self-limiting.

Weeks 27 through 56, Deceleration. The SCALE trial's primary endpoint sits here: 8.0% mean weight loss at 56 weeks. The rate of loss slows as the body adjusts to a new equilibrium. Cardiovascular markers, blood pressure, and lipid profiles continue to improve. Many community users transition to semaglutide or tirzepatide during this window if they want additional loss. Those who stay on liraglutide report satisfaction with maintained weight and improved metabolic markers. Cost becomes the primary concern at this stage. Gallstone risk increases with prolonged weight loss; cholecystitis occurred in roughly 2.2% of SCALE participants.

Detailed Timeline: Science vs Community

Weeks 1–4
Science

Dose advances weekly: 0.6 → 1.2 → 1.8 → 2.4 mg. Appetite suppression measurable by week 2. GI side effects peak during dose steps.

Community

Nausea most common complaint. Appetite noticeably reduced within 3–5 days of first injection. Most see 1–3 lb loss in first month from reduced caloric intake.

Weeks 5–8
Science

At 3.0 mg, maximal GLP-1 receptor engagement. ~2–4% body weight loss expected by week 8 in SCALE trial data.

Community

"Food noise" reduced. Smaller portions feel satisfying. GI side effects typically improving from peak. 2–5 lb loss reported in this window by most users.

Weeks 9–26
Science

Steady progressive weight loss at 0.5–1 lb/week average. Blood glucose improvements measurable. SCALE data shows ~6% weight loss by week 26.

Community

Most users report consistent loss. Some plateau at 1–2 month marks: often resolve with caloric adjustment or dose confirmation. Hair thinning may appear (telogen effluvium from weight loss, typically self-limiting).

Weeks 27–56
Science

SCALE trial: 8.0% mean weight loss at 56 weeks. Rate slows as body adjusts. Cardiovascular markers, blood pressure, and lipid improvements continue.

Community

Many users switch to semaglutide or tirzepatide in this window for additional loss. Those who stay report satisfaction with maintained weight and improved metabolic markers. Cost becomes the main issue at this stage.

Pharmacokinetics

Half-Life
13h
Bioavailability
SC: ~55%
Tmax
8-12 hours
Data Confidence
high

Source: FDA Prescribing Information (Victoza), Section 12.3

Pharmacokinetics: Active Dose Over Time

t½ = ~13 hours

Disclaimer: This curve is a simplified first-order exponential decay model. Actual pharmacokinetics vary based on injection site, individual metabolism, body composition, and other factors. Half-life values are approximate and based on available preclinical and clinical literature. Many research peptides lack formal human pharmacokinetic studies. This is for educational purposes only, not medical advice.

Molecular Profile

Amino Acids
31
Sequence
HAEGTFTSDVSSYLEGQAAKEFIAWLVRGRG
HydrophobicPolarPositiveNegativeSpecialHow we generate these icons
Identifiers

Who Should Consider Liraglutide

  • Adults with BMI ≥30 (or ≥27 with weight-related comorbidity)
  • Type 2 diabetics needing glycemic control with cardiovascular benefit
  • Adolescents aged 12+ with obesity
  • People who want a daily GLP-1 with faster side-effect clearance than weekly options
  • Those new to GLP-1 therapy who prefer a conservative start

Related Peptides

What Changed for Liraglutide

  1. Safety

    Corrected Oct 14, 2026: liraglutide with insulin or a sulfonylurea may call for a lower dose of that drug, not a do-not-combine, per the Victoza label.

    What this does not mean: The risk is real: hypoglycemia, including severe hypoglycemia. Victoza says to consider a lower insulin or sulfonylurea dose when starting (section 7.2). Saxenda adds glucose checks in type 2 diabetes (section 5.4).

    Source: Victoza (liraglutide) prescribing information (openFDA label record, SPL version 31, effective Oct 14, 2025; captured as the same-version DailyMed SPL XML) (opens in a new tab) · Saved copy

  2. Safety

    Corrected Oct 13, 2026: liraglutide lowered pill hormone peaks 12 to 13% with no drop in AUC, and no backup contraception is advised, per the Saxenda label.

    Before: Oral contraceptives: Cmax reduced by 12%, take at least 1 hour before injection; additional contraceptive precautions recommended during initiation and dose escalation (GLP-1 class wording) After: Cmax down 12% (ethinyl estradiol) and 13% (levonorgestrel), Tmax 1.5 hours later, AUC not lowered. The Saxenda and Victoza labels set no dose timing and call for no backup contraception

    What this does not mean: The page had said to take the pill 1 hour before the injection; that timing comes from the Byetta and Adlyxin labels. The tirzepatide and orforglipron labels do call for backup contraception.

    Source: Saxenda (liraglutide) prescribing information (openFDA label record, SPL version 22, effective Feb 25, 2026) (opens in a new tab) · Saved copy

  3. Regulatory

    FDA extended comments on its 503B proposal for semaglutide, tirzepatide and liraglutide to Jul 30, 2026, per Federal Register 2026-12937.

    What this does not mean: An extension of the comment period only. FDA has not made a final decision on the proposal.

    Also covers: Semaglutide, Tirzepatide

    Source: Federal Register 2026-12937 (91 FR 38719, Jun 26, 2026) (opens in a new tab) · Saved copy

  4. Regulatory

    FDA proposed not to include semaglutide, tirzepatide and liraglutide on the 503B bulks list on May 1, 2026, per Federal Register 2026-08552.

    What this does not mean: A proposal, not a final decision. It does not touch the FDA-approved brand products; it concerns bulk substances for outsourcing facilities.

    Also covers: Semaglutide, Tirzepatide

    Source: Federal Register 2026-08552 (91 FR 23431, May 1, 2026) (opens in a new tab) · Saved copy

  5. Safety

    Saxenda labeling supplement S-025 took the suicidal behavior and ideation warning off the label on Feb 25, 2026, per the updated FDA label.

    Source: Saxenda (liraglutide) prescribing information (openFDA label record, SPL version 22, effective Feb 25, 2026) (opens in a new tab) · Saved copy

  6. Safety

    FDA asked makers to take the suicidal behavior and ideation warning off Saxenda, Wegovy and Zepbound labels on Jan 13, 2026, per an FDA safety communication.

    What this does not mean: FDA found no increased risk of suicidal ideation or behavior in its review. The diabetes-only GLP-1 labels never carried this warning.

    Also covers: Semaglutide, Tirzepatide

    Source: FDA Drug Safety Communication, Jan 13, 2026: FDA requests removal of suicidal behavior and ideation warning from GLP-1 RA medications (opens in a new tab) · Saved copy

Peptide Schedule Research TeamReviewed Apr 7, 20269 Citations

References

  1. [1]LEADER Trial: Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes (opens in a new tab)PubMed (opens in a new tab)PubMed
  2. [2]A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management (Pi-Sunyer et al., N Engl J Med 2015) (opens in a new tab)(n=3,731,)PubMed (opens in a new tab)PubMed

Related Resources

Related Tools

Storage & Stability

Before Reconstitution
Not applicable: pre-filled pen, store unused pens refrigerated at 2-8°C until expiration date
After Reconstitution
In-use pen can be kept at room temperature (up to 30°C) or refrigerated for 30 days
Temperature
2-8°C (36-46°F) before first use; up to 30°C (86°F) after first use

Frequently Asked Questions

The Saxenda label starts at 0.6 mg daily subcutaneous for one week, then titrates by 0.6 mg each week until reaching 3.0 mg daily. For diabetes (Victoza), the max dose is 1.8 mg daily. Skipping titration steps significantly increases nausea and vomiting rates.

Both are GLP-1 agonists from Novo Nordisk. In STEP 8 (PMC8753508), semaglutide 2.4 mg weekly produced 15.8% weight loss versus 6.4% for liraglutide 3 mg daily at 68 weeks. Liraglutide requires daily injections; semaglutide is once weekly. Liraglutide does hold a pediatric approval for ages 12+, which semaglutide does not.

Nausea (39%), diarrhea (21%), constipation (19%), and vomiting (16%) per the SCALE trials. GI side effects peak during the first 4-8 weeks of titration. The FDA black box warning covers medullary thyroid carcinoma risk from rodent studies. Pancreatitis, gallbladder events, and acute kidney injury are rare but documented risks.

Yes. Victoza (liraglutide 1.8 mg) is FDA-approved for type 2 diabetes (2010). Saxenda (liraglutide 3.0 mg) is FDA-approved for chronic weight management (2014). The LEADER trial (n=9,340) also established cardiovascular benefit, leading to a CV risk reduction indication.

Appetite reduction begins within the first week at the 0.6 mg starting dose. Weight loss becomes measurable by weeks 4-8 as the dose titrates up. The SCALE Obesity trial showed 8% mean weight loss at 56 weeks. Maximum effect requires reaching and maintaining the 3.0 mg daily dose.